StockData
ResMed Inc logo

ResMed Inc (RMD) shareholders

RMDNYSESurgical & Medical Instruments & ApparatusFiscal year ends June 30Also trades as RSMDF
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 21/3014% below fair value
$237.85−0.34 (-0.14%)

Close on Nov 17, 2026Market cap $33.46BP/E 21.7Yield 1.01%

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100M
Shares held, 13F filers
Institutional holders
885
93 new, 137 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 29 sales
Net sold $20.16M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.12,783,7158.70%13G (passive) amendmentDec 31, 2023
Vanguard Capital Management11,961,7068.21%13G (passive)Mar 31, 2026
AustralianSuper Pty Ltd8,276,3815.70%13G (passive)Jun 30, 2026
Vanguard Portfolio Management7,886,4895.41%13G (passive)Mar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of RMDValueChange% of portfolio
BlackRock, Inc.12,317,194–$2.40B+223,1710.04%
Vanguard Capital Management LLC9,474,129–$1.85B+7,7130.04%
Vanguard Portfolio Management LLC7,913,661–$1.54B+49,7390.07%
State Street Corp6,680,735–$1.30B+37,5670.04%
Geode Capital Management, LLC4,352,320–$845.16M−5530.05%
Bank of New York Mellon Corp4,197,610–$818.03M−727,7760.13%
First Trust Advisors LP2,278,696–$444.07M+740,8710.26%
Invesco Ltd.2,063,578–$402.15M+106,9640.03%
Morgan Stanley1,928,931–$375.91M−757,8900.02%
Northern Trust Corp1,696,674–$330.65M−29,0190.04%
Nordea Investment Management Ab1,388,008–$269.57M+354,6270.22%
Deutsche Bank AG\1,322,313–$257.69M−100,5520.07%
UBS Group AG1,289,300–$251.26M+562,4890.03%
Swedbank AB1,274,897–$248.45M−75,3370.21%
Charles Schwab Investment Management Inc1,222,473–$238.24M+87,1740.03%
Goldman Sachs Group Inc1,160,426–$226.14M+156,2210.02%
Arrowstreet Capital, Limited Partnership1,129,739–$220.16M+679,4890.10%
Dimensional Fund Advisors LP1,123,577–$219.00M+119,3590.04%
Legal & General Group Plc942,614–$183.70M−47,7470.04%
Aqr Capital Management LLC910,623–$177.14M+560,7830.06%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares heldNew / addedReduced / closedShares boughtShares sold
Q2 2026885100M93 / 312358 / 13711M8M
Q1 202694398M105 / 362322 / 9925M6M
Q4 202594897M114 / 333340 / 10011M5M
Q3 202595093M119 / 345325 / 756M7M
Q2 202592093M120 / 355323 / 766M6M
Q1 202588594M109 / 348290 / 827M3M
Q4 202487191M151 / 333264 / 699M6M
Q3 202480388M111 / 324258 / 7318M6M
Q2 202477387M117 / 309241 / 548M9M
Q1 202471789M98 / 292217 / 6111M6M
Q4 202368884M112 / 246242 / 749M13M
Q3 202365988M61 / 248255 / 1239M17M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

707 funds held RMD in Q2 2026, 73% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of RMDValue% of fundAs of
Vanguard Total Stock Market Index Fund4,605,309–$897.48M0.04%Jun 30, 2026
Vanguard 500 Index Fund3,758,092–$732.38M0.04%Jun 30, 2026
Vanguard Mid-Cap Index Fund3,143,005–$612.51M0.27%Jun 30, 2026
iShares Core S&P 500 ETF1,994,871–$388.76M0.04%Jun 30, 2026
Vanguard Growth Index Fund1,866,016–$363.65M0.10%Jun 30, 2026
Fidelity 500 Index Fund1,864,247–$355.27M0.04%May 31, 2026
First Trust Rising Dividend Achievers ETF1,396,495–$272.15M1.11%Jun 30, 2026
Vanguard Mid-Cap Growth Index Fund1,111,305–$216.57M0.62%Jun 30, 2026
State Street(R) Health Care Select Sector SPDR(R) ETF1,024,772–$199.71M0.49%Jun 30, 2026
Invesco S&P 500 Equal Weight ETF963,450–$203.27M0.21%Jul 31, 2026
Vanguard Dividend Appreciation Index Fund820,726–$173.16M0.13%Jul 31, 2026
Vanguard Institutional Index Fund787,464–$153.46M0.04%Jun 30, 2026
iShares U.S. Medical Devices ETF679,275–$132.38M4.38%Jun 30, 2026
First Trust Capital Strength ETF675,234–$131.59M1.72%Jun 30, 2026
iShares Russell Mid-Cap ETF597,936–$116.53M0.20%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Michael J. FarrellChairman and CEO, Director473,864Nov 13, 2026
Aaron BloomerChief Financial Officer7,977Nov 13, 2026
Michael J. RiderGlobal General Counsel10,417Nov 13, 2026
Justin LeongChief Product Officer35,489Oct 1, 2026
Brett SandercockChief Financial Officer83,495May 4, 2026
Kaushik GhoshalChief Commercial Officer, SaaS19,430Aug 5, 2025
Witte Jan DeDirector4,201Nov 13, 2026
Peter C. FarrellDirector1,095,808Nov 13, 2026
Harjit GillDirector10,904Nov 13, 2026
Nicole Mowad-NassarDirector777Nov 26, 2025
Christopher DelOreficeDirector2,423Nov 24, 2025
Carol BurtDirector18,816Nov 24, 2025
John HernandezDirector5,118Nov 24, 2025
Desney TanDirector6,002Nov 24, 2025
Ronald R. TaylorDirector24,771Nov 24, 2025
Karen DrexlerDirector10,602Nov 24, 2025
Richard SulpizioDirector17,796Nov 21, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Michael J. Farrell
Chairman and CEO, Director
Nov 11, 2026Tax withholding−2,435.843$234.11$570.26K471,774
Michael J. Farrell
Chairman and CEO, Director
Nov 11, 2026Tax withholding−2,209.793$234.11$517.33K474,209
Michael J. Farrell
Chairman and CEO, Director
Nov 11, 2026Tax withholding−3,465.749$234.11$811.37K476,419
Aaron Bloomer
Chief Financial Officer
Nov 11, 2026Tax withholding−1,095.137$234.11$256.38K7,977
Peter C. Farrell
Director
Nov 11, 2026Tax withholding−169.142$234.11$39.60K51,634
Michael J. Rider
Global General Counsel
Nov 11, 2026Tax withholding−172.993$234.11$40.50K10,417
Michael J. Rider
Global General Counsel
Nov 11, 2026Tax withholding−724.414$234.11$169.59K10,590
Michael J. Rider
Global General Counsel
Nov 11, 2026Tax withholding−498.624$234.11$116.73K11,314
Michael J. Rider
Global General Counsel
Nov 11, 2026Tax withholding−547.469$234.11$128.17K11,813
Witte Jan De
Director
Nov 11, 2026Tax withholding−59.981$234.11$14.04K4,201
Harjit Gill
Director
Nov 11, 2026Tax withholding−35.731$234.11$8.36K10,904
Michael J. Farrell
Chairman and CEO, Director
Nov 9, 2026Sale(10b5-1 plan)−4,993$235.35$1.18M479,803
Michael J. Farrell
Chairman and CEO, Director
Nov 9, 2026Option exercise+4,310$146.34$630.73K484,796
Michael J. Farrell
Chairman and CEO, Director
Nov 9, 2026Option exercise+683$146.34$99.95K480,486
Michael J. Rider
Global General Counsel
Oct 23, 2026Sale(10b5-1 plan)−400$255.00$102.00K12,318
Michael J. Farrell
Chairman and CEO, Director
Oct 7, 2026Sale(10b5-1 plan)−4,991$226.33$1.13M479,803
Michael J. Farrell
Chairman and CEO, Director
Oct 7, 2026Option exercise+4,991$146.34$730.38K484,794
Michael J. Farrell
Chairman and CEO, Director
Sep 8, 2026Sale(10b5-1 plan)−4,991$222.44$1.11M466,256
Michael J. Farrell
Chairman and CEO, Director
Sep 8, 2026Option exercise+4,991$146.34$730.38K471,247
Peter C. Farrell
Director
Sep 2, 2026Sale(10b5-1 plan)−970$234.73$227.69K51,803
Justin Leong
Chief Product Officer
Aug 14, 2026Award+6,461––35,489
Michael J. Rider
Global General Counsel
Aug 14, 2026Award+3,230––12,718
Michael J. Farrell
Chairman and CEO, Director
Aug 14, 2026Award+13,547––479,803
Aaron Bloomer
Chief Financial Officer
Aug 14, 2026Award+9,072––9,072
Michael J. Farrell
Chairman and CEO, Director
Aug 7, 2026Sale(10b5-1 plan)−4,991$205.69$1.03M466,256
Michael J. Farrell
Chairman and CEO, Director
Aug 7, 2026Option exercise+4,991$146.34$730.38K471,247
Peter C. Farrell
Director
Aug 5, 2026Sale(10b5-1 plan)−8,000$225.00$1.80M52,773
Michael J. Farrell
Chairman and CEO, Director
Jul 7, 2026Sale(10b5-1 plan)−4,991$218.55$1.09M466,223
Michael J. Farrell
Chairman and CEO, Director
Jul 7, 2026Option exercise+4,991$146.34$730.38K471,214
Michael J. Farrell
Chairman and CEO, Director
Jun 8, 2026Sale(10b5-1 plan)−4,991$193.96$968.05K466,256
Michael J. Farrell
Chairman and CEO, Director
Jun 8, 2026Option exercise+4,991$146.34$730.38K471,214
Michael J. Rider
Global General Counsel
Jun 1, 2026Tax withholding−268.74$190.57$51.21K9,488
Michael J. Farrell
Chairman and CEO, Director
May 7, 2026Sale(10b5-1 plan)−4,991$207.82$1.04M466,223
Michael J. Farrell
Chairman and CEO, Director
May 7, 2026Option exercise+4,991$146.34$730.38K471,214
Michael J. Farrell
Chairman and CEO, Director
Apr 7, 2026Sale(10b5-1 plan)−4,991$225.50$1.13M466,223
Michael J. Farrell
Chairman and CEO, Director
Apr 7, 2026Option exercise+4,991$146.34$730.38K471,214
Brett Sandercock
Chief Financial Officer
Apr 1, 2026Sale(10b5-1 plan)−1,000$224.31$224.31K83,495
Peter C. Farrell
Director
Apr 1, 2026Sale(10b5-1 plan)−2,000$225.00$450.00K60,773
Michael J. Farrell
Chairman and CEO, Director
Mar 9, 2026Sale(10b5-1 plan)−4,991$251.03$1.25M466,223
Michael J. Farrell
Chairman and CEO, Director
Mar 9, 2026Option exercise+4,991$146.34$730.38K471,214
Peter C. Farrell
Director
Mar 4, 2026Sale(10b5-1 plan)−2,000$260.22$520.44K62,773
Brett Sandercock
Chief Financial Officer
Mar 2, 2026Sale(10b5-1 plan)−1,000$254.30$254.30K84,495
Michael J. Farrell
Chairman and CEO, Director
Feb 9, 2026Sale(10b5-1 plan)−4,991$273.78$1.37M466,223
Michael J. Farrell
Chairman and CEO, Director
Feb 9, 2026Option exercise+4,991$146.34$730.38K471,214
Michael J. Rider
Global General Counsel
Feb 4, 2026Sale(10b5-1 plan)−50$260.00$13.00K9,691
Peter C. Farrell
Director
Feb 4, 2026Sale(10b5-1 plan)−2,000$251.31$502.62K64,773
Brett Sandercock
Chief Financial Officer
Feb 2, 2026Sale(10b5-1 plan)−1,000$257.03$257.03K85,495
Peter C. Farrell
Director
Jan 7, 2026Sale(10b5-1 plan)−2,000$248.83$497.66K66,773
Michael J. Farrell
Chairman and CEO, Director
Jan 7, 2026Option exercise+4,991$146.34$730.38K471,214
Michael J. Farrell
Chairman and CEO, Director
Jan 7, 2026Sale(10b5-1 plan)−4,991$248.46$1.24M466,223
Michael J. Rider
Global General Counsel
Jan 2, 2026Sale(10b5-1 plan)−50$241.75$12.09K9,741
Brett Sandercock
Chief Financial Officer
Jan 2, 2026Sale(10b5-1 plan)−1,000$241.75$241.75K86,495
Michael J. Farrell
Chairman and CEO, Director
Dec 8, 2025Sale(10b5-1 plan)−4,991$251.41$1.25M466,223
Michael J. Farrell
Chairman and CEO, Director
Dec 8, 2025Option exercise+4,991$146.34$730.38K471,214
Peter C. Farrell
Director
Dec 3, 2025Sale(10b5-1 plan)−2,000$251.47$502.94K68,773
Michael J. Rider
Global General Counsel
Dec 1, 2025Sale(10b5-1 plan)−50$244.16$12.21K9,791
Brett Sandercock
Chief Financial Officer
Dec 1, 2025Sale(10b5-1 plan)−1,000$244.16$244.16K87,495
Witte Jan De
Director
Nov 25, 2025Sale(10b5-1 plan)−2,055$255.00$524.03K4,261
Christopher DelOrefice
Director
Nov 20, 2025Award+1,073––2,423
Ronald R. Taylor
Director
Nov 20, 2025Award+1,073––24,771

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
10M shares short
Days to cover
7.0
At 1M shares a day
Change since last report
-12.2%
From 12M shares
Short volume, 20 days
67.9%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ResMed's stock actually held short. Settlement fails (shares not delivered on time) peaked at 84,382 shares on Sep 15, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Michael J. Farrell
Officer, Director
Nov 9, 20264,993$1.18MNov 9, 2026Stock Option Exercise
Michael J. Rider
Officer
Oct 23, 2026400$102.00KOct 23, 2026Restricted Stock Vesting
Michael J. Farrell
Officer, Director
Oct 7, 20264,991$1.13MOct 7, 2026Stock Option Exercise
Michael J. Farrell
Officer, Director
Sep 8, 20264,991$1.13MSep 8, 2026Stock Option Exercise
Peter C. Farrell
Director
Sep 2, 2026970$227.61KSep 2, 2026Stock Option
Michael J. Farrell
Officer, Director
Aug 7, 20264,991$1.03MAug 7, 2026Stock Option Exercise
Peter C. Farrell
Director
Aug 5, 20268,000$1.80MAug 5, 2026Stock Option
Michael J. Farrell
Officer, Director
Jul 7, 20264,991$1.09MJul 7, 2026Stock Option Exercise
Michael J. Farrell
Officer, Director
Jun 8, 20264,991$968.25KJun 8, 2026Stock Option Exercise
Brett Sandercock
Former Officer
May 27, 20268,000$1.67MMay 27, 2026Restricted Stock Vesting
Michael J. Farrell
Officer, Director
May 7, 20264,991$1.04MMay 7, 2026Option Granted - 11/21/2019
Michael J. Farrell
Officer, Director
Apr 7, 20264,991$1.13MApr 7, 2026Option Granted - 11/21/2019
Brett Sandercock
Officer
Apr 1, 20261,000$224.31KApr 1, 2026Restricted Stock Vesting
Peter C. Farrell
Director
Apr 1, 20262,000$449.92KApr 1, 2026Stock Option
Michael J. Farrell
Officer, Director
Mar 9, 20264,991$1.25MMar 9, 2026Options Granted 11/21/2019

Congress trades

11 trades in ResMed reported by 5 members of the House

MemberTypeTradedAmountFiled
Kelly Louise Morrison
MN03
SoldJun 4, 2025$1K–15KJun 18, 2025
Kelly Louise Morrison
MN03
SoldJun 4, 2025$1K–15KJun 18, 2025
Kelly Louise Morrison
MN03
SoldJun 4, 2025$1K–15KJun 18, 2025
Kelly Louise Morrison
MN03
SoldJun 4, 2025$1K–15KJun 18, 2025
Kelly Louise Morrison
MN03
SoldApr 28, 2025$1K–15KMay 13, 2025
Rob Bresnahan
PA08 · joint account
SoldJan 13, 2025$1K–15KFeb 13, 2025
Peter Meijer
MI03
SoldFeb 16, 2021$1K–15KMar 16, 2021
Susie Lee
NV03 · joint account
SoldFeb 27, 2019$1K–15KMar 12, 2019
Bradley S. Schneider
IL10 · spouse
SoldFeb 5, 2019$250KFeb 17, 2019
Bradley S. Schneider
IL10 · spouse
BoughtMar 21, 2018$50K–100KMar 31, 2018
Bradley S. Schneider
IL10 · spouse
BoughtMar 2, 2018$100K–250KMar 31, 2018

See a number that looks wrong?